{"entity":{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","aka":["ImmVira Pharma Co. Ltd"],"tldr":"ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011.","summary":"ImmVira Pharma appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 1/2, 2), testing Herpes Virus C5252, T3011 in glioma, malignant, nonmuscle-invasive bladder cancer, solid tumor, melanoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by ImmVira Pharma","url":"https://clinicaltrials.gov/search?spons=ImmVira%20Pharma"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07243340","nct06971614","nct04370587"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Shenzhen, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/immvira-pharma/","neighbours":{"trial":[{"id":"nct04370587","kind":"trial","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","route":"/trials/nct04370587/"},{"id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","route":"/trials/nct07243340/"},{"id":"nct06971614","kind":"trial","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","route":"/trials/nct06971614/"}]}}